The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin | Zendy

Kostas Stylianou | Zendy; Ioannis Petrakis | Zendy; Vasiliki Mavroeidi | Zendy; Stavros Stratakis | Zendy; Eleftheria Vardaki | Zendy; Kostas Perakis | Zendy; Spyros Stratigis | Zendy; Andreas Passam | Zendy; Eva Papadogiorgaki | Zendy; K. Giannakakis | Zendy; Lydia Nakopoulou | Zendy; Eugene Daphnis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin

Author(s) -

Kostas Stylianou,

Ioannis Petrakis,

Vasiliki Mavroeidi,

Stavros Stratakis,

Eleftheria Vardaki,

Kostas Perakis,

Spyros Stratigis,

Andreas Passam,

Eva Papadogiorgaki,

K. Giannakakis,

Lydia Nakopoulou,

Eugene Daphnis

Publication year - 2010

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfq496

Subject(s) - pi3k/akt/mtor pathway , protein kinase b , rptor , lupus nephritis , medicine , cancer research , sirolimus , signal transduction , immunology , biology , microbiology and biotechnology , disease

The mammalian target of rapamycin (mTOR) inhibitor, rapamycin, has been shown to inhibit the progression of murine lupus nephritis by virtue of its potent immunosuppressive properties. The phosphoinositol-3-kinase (PI3K)/Akt pathway is a major upstream activator of mTOR and has been implicated in the propagation of cancer and autoimmunity. However, the activation status of the PI3K/Akt/mTOR pathway in lupus nephritis has not been studied so far.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research